Five Prime Therapeutics, Inc.

Pact Pharma, Inc.

Adoc Ssf, LLC

Barbara Sennino

Thomas Brennan

Alex Franzusoff

Stefanie Mandl-Cashman

David Bellovin

David Busha

Kyle Jacoby

Songming Peng

Olivier Dalmas

Xiaoyan Robert Bao

John Gagnon

Michael M Dubreuil

Boi Bryant Quach

Duo An

Susannah D Barbee

Ursula Jeffry

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

CD80 extracellular domain polypeptides and their use in cancer treatment

Disclosed herein are antigenic peptide-MHC complexes, termed comPACT polypeptides and comPACT polynucleotides, and methods of producing such complexes. Also discloses herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells with high accuracy. Dual particle detection approaches for detection of neoantigen specific T cells with improved sensitivity and specificity are provided. Signal to noise ratio analysis of isolated T cells for detection of neoantigen-specific T cells with improved T cells is also provided.

Compositions and methods for identification of antigen specific T cells

Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.

Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy

This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.

Methods of treatment with CD80 extracellular domain polypeptides

This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

Growing community of inventors

San Francisco, CA, United States of America

Barbara Sennino